Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 15, 2022 - Issue
Submit an article Journal homepage
175
Views
5
CrossRef citations to date
0
Altmetric
Short Report

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma

Ana Gómez-Bastero Fernández1 Asthma Unit of Pneumology, Virgen Macarena University Hospital, Seville, SpainORCID Iconhttps://orcid.org/0000-0002-4173-783XView further author information
ORCID Icon,
Juan Francisco Medina Gallardo2 Asthma Unit of Pneumology, Virgen Del Rocio University Hospital, Seville, SpainView further author information
,
Julio Delgado Romero3 Asthma Unit of Allergy, Virgen Macarena University Hospital, Seville, SpainView further author information
,
Auxiliadora Romero Falcón2 Asthma Unit of Pneumology, Virgen Del Rocio University Hospital, Seville, SpainView further author information
,
Cristina Benito Bernáldez1 Asthma Unit of Pneumology, Virgen Macarena University Hospital, Seville, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1803-1342View further author information
ORCID Icon,
Javier Gallego Borrego4 Asthma Unit of Pneumology, Valme University Hospital, Seville, SpainView further author information
&
Francisco Javier Álvarez-Gutiérrez2 Asthma Unit of Pneumology, Virgen Del Rocio University Hospital, Seville, SpainORCID Iconhttps://orcid.org/0000-0002-0175-2824View further author information
ORCID Icon show all
Pages 727-735 | Published online: 25 May 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yen Chung, Diego J. Maselli, Fan Mu, Erin E. Cook, Danni Yang, Joshua A. Young, Keith A. Betts, Eduardo Genofre & Donna Carstens. (2023) Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study. Journal of Medical Economics 26:1, pages 954-962.
Read now

Articles from other publishers (4)

Giulia Scioscia, Pasquale Tondo, Santi Nolasco, Corrado Pelaia, Giovanna Elisiana Carpagnano, Maria Filomena Caiaffa, Giuseppe Valenti, Angelantonio Maglio, Francesco Papia, Massimo Triggiani, Nunzio Crimi, Girolamo Pelaia, Alessandro Vatrella, Maria Pia Foschino Barbaro & Claudia Crimi. (2023) Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience. Journal of Clinical Medicine 12:13, pages 4362.
Crossref
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, Carla Maria Irene Quarato, Cristiano Caruso, Corrado Pelaia, Andrea Portacci & Claudia Crimi. (2023) Switching Biological Therapies in Severe Asthma. International Journal of Molecular Sciences 24:11, pages 9563.
Crossref
Alessandra Vultaggio, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Maria D’Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Gianenrico Senna, Marco Benci, Silvia Boarino & Jan Walter Schroeder. (2023) Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respiratory Research 24:1.
Crossref
Laura J. Walsh, Deborah Casey, Punitha Vairamani, Fiona Arnott, Barry J. Plant & Desmond M. Murphy. (2023) Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab. Frontiers in Allergy 3.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.